A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma
Author:
Funder
Foro Italico University of Rome
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference30 articles.
1. Anon (2020) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s084lbl.pdf#page=89.
2. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300;Bang;Ann. Oncol.,2018
3. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N. Engl. J. Med.,2017
4. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement;BMJ (OPEN ACCESS);BMJ,2009
5. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Severe weight loss during PD-1 treatment is a risk sign of poor prognosis for advanced GC patients;International Journal of Clinical Oncology;2024-07-30
2. Evaluation of reported claims of sex-based differences in treatment effects across meta-analyses: A meta-research study;2024-07-10
3. Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis;Frontiers in Immunology;2024-06-20
4. Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review;Cancer Cell International;2024-01-05
5. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors;BMC Cancer;2023-12-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3